Do you think suitors can be other interested companies who wants to have a deal during the trial just like we get with daybue? There are a lot of permutation combinations here, if the end point meets are favourable and end point meets are unfavourable. I assume on a favourable end point meets a deal in on the cards. But even if we leave all that alone, how about the present SP with present conditions and no phase 3 trial agreement with FDA. We are highly under priced as a growing company. Right now PE is less than 10 and it will remain less than 10 in 2 years again even without a positive phase 3 trial result. dyor
NEU Price at posting:
$9.86 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)